Hershey's first quarter looked like a comeback story. Sales rose 10.6% and profit jumped 93.6% as cost pressures eased.
Inside the report sat a stranger detail. One of the firm's brands is getting a real lift from weight-loss drugs.
Ice Breakers, the third-biggest line in Hershey's lineup, grew retail sales by more than 8% in the quarter. Hershey credits part of that to GLP-1 users - people on drugs like Ozempic and Wegovy - reaching for mints to take the edge off nausea and dry mouth.
Q1 sales hit $3.10 billion versus the $3.03 billion call. Adjusted EPS came in at $2.35, beating the $2.04 Wall Street had penciled in.
Net income rose to $435.1 million, up 93.6% from a weaker quarter a year ago when high prices and cocoa costs were squeezing margins. EPS - profit per share of stock - is the line investors track most closely.
Operating margin jumped to 20.6% from 13.2% in the same quarter last year. Stronger pricing across the lineup did most of the work.
CEO Kirk Tanner credited Hershey's and Reese's, which lifted non-seasonal retail sales 11% and 10%. Organic sales rose 7.9% on the year, even as overall volumes still slipped 2%.
That mix - higher prices, slightly fewer units sold - is what a packaged-goods comeback looks like.
For most of Hershey's lineup, GLP-1 drugs are still a real worry. Shoppers on the drugs eat less of nearly everything.
The firm has flagged GLP-1 use, SNAP changes, and faster health and wellness trends as things it's watching for the rest of the year. SNAP is the federal food-stamp program, and changes there can hit grocery-aisle volumes.
Ice Breakers is the surprise the other way. Mints help manage nausea and the dry mouth that comes with slow digestion on those drugs.
Hershey now sees Ice Breakers as a brand it can lean on for health perks, not just flavor.
Functional foods - the items built around perks like better sleep or gut health - are one of the fastest-growing parts of the snack aisle.
Overseas sales remain a soft spot, with volumes down about 2%. The unit is set up as a longer-term project, not a 2026 driver.
Hershey kept its 2026 guide, and the comeback in Q1 looks real on margins and on the top line. The bigger question is whether Ice Breakers can grow into a meaningful piece of the portfolio while the rest of the snack aisle keeps fighting the GLP-1 headwind.
If Hershey turns Ice Breakers into a functional brand built around digestion and breath, the upside could outrun the chocolate drag. If not, this quarter is a margin bounce, not a strategy shift.
Watch the next earnings call for signs of a functional Ice Breakers launch. That would tell investors how seriously the company is treating the trend.
The other thing to track is volume. Prices did the work this quarter, and that game has limits if shoppers keep cutting back on candy.
